<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599271</url>
  </required_header>
  <id_info>
    <org_study_id>P500-0118</org_study_id>
    <nct_id>NCT03599271</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)</brief_title>
  <official_title>The ASCEND Study: A Clinical Evaluation of the UP Drug-Coated Device in Patients With Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intersect ENT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intersect ENT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the ASCEND Study is to assess the safety, performance, and efficacy of the&#xD;
      Intersect ENT UP Drug-Coated Device when used in chronic rhinosinusitis (CRS) patients&#xD;
      undergoing balloon dilation of frontal sinus ostia (FSO)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter study enrolling two consecutive cohorts:&#xD;
&#xD;
      PK cohort (N=5): A non-randomized cohort to assess the systemic safety and performance of the&#xD;
      UP Drug-Coated Device for in-office bilateral dilation of the FSO (2 inflations in each FSO&#xD;
      for a total of 4 inflations per device). Subsequently, the UP Drug-Coated Device may be used&#xD;
      to dilate any sphenoid or maxillary sinuses.&#xD;
&#xD;
      Randomized cohort (N=70): A randomized, intra-patient controlled, double-blind cohort of 70&#xD;
      subjects to assess the safety and efficacy of the UP Drug-Coated Device used for in-office&#xD;
      dilation of the FSO. The FSO randomized to the treatment (Treatment) will undergo dilation&#xD;
      using the UP Drug-Coated Device (2 inflations per device) while the contralateral FSO&#xD;
      (Control) will be dilated with a UP Control Device (2 inflations per device).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>A PK non-randomized cohort in 5 participants, followed by a randomized, intra-patient controlled double-blind cohort in 70 participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The randomized cohort is double-blinded, which both participants and outcome assessor being masked to treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Randomized Cohort: Difference in Patency Grade of FSO</measure>
    <time_frame>30 days</time_frame>
    <description>Difference in the patency grade of the FSO between treatment sides at Day 30, as determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. Patency of the FSO assessed endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip (&quot;suction tip&quot;) and graded on a 5-point scale as follows - 0: Occluded (no opening visible); 1: Significantly stenosed (not occluded, but unable to pass the 3-mm suction tip); 2: Moderately stenosed (able to easily pass the 3-mm suction tip with no additional space around it); 3: Minimally stenosed (able to easily pass the 3-mm suction tip with additional 1-2 mm space around it); 4: Completely patent (able to easily pass the 3-mm suction tip with additional &gt;2 mm space around it)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants in the PK Cohort With Successful Dilation of Attempted FSO at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Successful dilation of attempted FSO using the Drug-Coated Device with no unanticipated serious adverse device effects. A successful dilation of the FSO is defined as insertion of the UP Drug-Coated Device into the targeted FSO followed by 2 consecutive, complete inflations of the balloon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: Estimated Frontal Sinus Ostia (FSO) Diameter</measure>
    <time_frame>30 days</time_frame>
    <description>The smallest and largest diameters of the FSO determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. FSO diameter estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort: Estimated Largest Frontal Sinus Ostia (FSO) Diameter</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort: Estimated Smallest Frontal Sinus Ostia (FSO) Diameter</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cohort: Total Sino-Nasal Outcomes Test Score (SNOT-22)</measure>
    <time_frame>Baseline, Day 14 and Day 30</time_frame>
    <description>SNOT-22 is a validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by patient on a 6-point scale as follows: 0: No problem; 1: Very mild problem; 2: Mild or slight problem; 3: Moderate problem; 4: Severe problem; 5: Problem as bad as it can be.&#xD;
Sum of all 22 questions constitutes the total SNOT-22 score with a maximum total score equal to 110.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Drug-Coated Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Sinus Dilation Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PK cohort- Drug-Coated Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Coated Device</intervention_name>
    <description>3000 mcg mometasone furoate-coated sinus dilation device</description>
    <arm_group_label>Drug-Coated Device</arm_group_label>
    <arm_group_label>PK cohort- Drug-Coated Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Device</intervention_name>
    <description>Sinus dilation device without drug</description>
    <arm_group_label>Control Sinus Dilation Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of CRS per the 2016, &quot;International Consensus Statement on Allergy&#xD;
             and Rhinology&quot; definition.&#xD;
&#xD;
          2. Bilateral disease in the frontal sinuses (Lund-Mackay score ≥ 1 on each side) on CT&#xD;
             scan within 30 days prior to enrollment in the PK cohort and prior to randomization in&#xD;
             the randomized cohort.&#xD;
&#xD;
          3. Patient has bilateral obstruction of the frontal recess/FSO due to scarring and/or&#xD;
             polypoid edema confirmed on endoscopy (patency grade of 0 or 1 for each FSO).&#xD;
&#xD;
          4. Balloon dilation of the FSO judged to be feasible and medically appropriate.&#xD;
&#xD;
          5. Patient has had prior ESS (&gt; 30 days with a healed mucosa) including bilateral&#xD;
             ethmoidectomy (anterior or total) and uncinectomy for better visualization of the FSO.&#xD;
&#xD;
          6. Balloon dilation of the FSO with a 6 mm balloon is judged to be feasible (use&#xD;
             light-assisted or image-guided instrument such as a frontal sinus seeker tip to&#xD;
             confirm access of each FSO) and medically appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Expanded amount of ethmoid polyposis (grade &gt; 2 PK cohort, grade ≥ 2 randomized&#xD;
             cohort).&#xD;
&#xD;
          2. Complications from prior ESS or balloon dilation procedure (e.g., cerebrospinal fluid&#xD;
             leak or injury to the skull base).&#xD;
&#xD;
          3. History of aspirin exacerbated respiratory disease (AERD).&#xD;
&#xD;
          4. Current smokers.&#xD;
&#xD;
          5. History of allergy or intolerance to mometasone furoate.&#xD;
&#xD;
          6. Oral-steroid dependent condition.&#xD;
&#xD;
          7. Evidence of acute rhinosinusitis, invasive fungal sinusitis or another disease or&#xD;
             condition expected to compromise survival or ability to complete assessments during&#xD;
             the 30-day follow-up period in the PK cohort and druing the 60-day follow-up period in&#xD;
             the randomized cohort.&#xD;
&#xD;
          8. Use of parenteral and injected steroids (e.g., Kenalog) 30 days prior to the baseline&#xD;
             procedure.&#xD;
&#xD;
          9. Use of oral steroids, budesonide or other sinus steroid irrigations/rinses or drops,&#xD;
             nebulized steroids administered nasally 14 days prior to screening in the PK cohort&#xD;
             and prior to baseline in the randomized cohort.&#xD;
&#xD;
         10. Glaucoma or posterior subcapsular cataract.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centers for Advanced ENT Care</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <results_first_submitted>March 4, 2021</results_first_submitted>
  <results_first_submitted_qc>April 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2021</results_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03599271/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03599271/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Randomized Cohort</title>
          <description>Randomized cohort (n=70) used a randomized intra-patient design in which the Drug-Coated Device was used to dilate randomized frontal sinus ostium and Control Device was used to dilate contralateral frontal sinus ostium.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device. Control Device: Sinus dilation device without drug.</description>
        </group>
        <group group_id="P2">
          <title>PK Cohort-Safety</title>
          <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Drug-Coated Device</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Control Device</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Cohort</title>
          <description>Randomized cohort (n=70) used a randomized intra-patient desgin which received Drug-Coated Device to dilate randomized frontal sinus ostium and control device in the randomized contralateral frontal sinus ostium.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device. Control Device: Sinus dilation device without drug.</description>
        </group>
        <group group_id="B2">
          <title>PK Cohort- Safety</title>
          <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="11.37"/>
                    <measurement group_id="B2" value="61.2" spread="10.94"/>
                    <measurement group_id="B3" value="54.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Allergic Rhinitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Aspirin Intolerance or Allergy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Repeated Courses of Corticosteroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CT Lund Mackay Score - Total</title>
          <description>The CT Lund-Mackay score is used to assess chronic rhinosinusitis. Each sinus (frontal, anterior ethmoidal cells, posterior ethmoidal cells, maxillary sinus, and sphenoid sinus) is scored from 0 (no abnormality), 1 (partial opacification) to 2 (complete opacification). The osteomeatal complex is scored from 0 (not obstructed) to 2 (obstructed). Each side is graded separately. A combined score from 0 to 24 is possible.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="2.94"/>
                    <measurement group_id="B2" value="11.0" spread="2.92"/>
                    <measurement group_id="B3" value="9.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior Endoscopic Sinus Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Randomized Cohort: Difference in Patency Grade of FSO</title>
        <description>Difference in the patency grade of the FSO between treatment sides at Day 30, as determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. Patency of the FSO assessed endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip (&quot;suction tip&quot;) and graded on a 5-point scale as follows - 0: Occluded (no opening visible); 1: Significantly stenosed (not occluded, but unable to pass the 3-mm suction tip); 2: Moderately stenosed (able to easily pass the 3-mm suction tip with no additional space around it); 3: Minimally stenosed (able to easily pass the 3-mm suction tip with additional 1-2 mm space around it); 4: Completely patent (able to easily pass the 3-mm suction tip with additional &gt;2 mm space around it)</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort - Treatment Arm</title>
            <description>Randomized cohort (n=70 patients) which received the Drug-Coated Device to dilate randomized frontal sinus ostium.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort - Control Arm</title>
            <description>Randomized cohort (n=70) which received Control Device to dilate randomized contralateral frontal sinus ostium.&#xD;
Control Device: Sinus dilation device without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Randomized Cohort: Difference in Patency Grade of FSO</title>
          <description>Difference in the patency grade of the FSO between treatment sides at Day 30, as determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. Patency of the FSO assessed endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip (&quot;suction tip&quot;) and graded on a 5-point scale as follows - 0: Occluded (no opening visible); 1: Significantly stenosed (not occluded, but unable to pass the 3-mm suction tip); 2: Moderately stenosed (able to easily pass the 3-mm suction tip with no additional space around it); 3: Minimally stenosed (able to easily pass the 3-mm suction tip with additional 1-2 mm space around it); 4: Completely patent (able to easily pass the 3-mm suction tip with additional &gt;2 mm space around it)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.00"/>
                    <measurement group_id="O2" value="1.5" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants in the PK Cohort With Successful Dilation of Attempted FSO at Baseline</title>
        <description>Successful dilation of attempted FSO using the Drug-Coated Device with no unanticipated serious adverse device effects. A successful dilation of the FSO is defined as insertion of the UP Drug-Coated Device into the targeted FSO followed by 2 consecutive, complete inflations of the balloon.</description>
        <time_frame>Baseline</time_frame>
        <population>'Analysis per patient.</population>
        <group_list>
          <group group_id="O1">
            <title>PK Cohort-Safety</title>
            <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants in the PK Cohort With Successful Dilation of Attempted FSO at Baseline</title>
          <description>Successful dilation of attempted FSO using the Drug-Coated Device with no unanticipated serious adverse device effects. A successful dilation of the FSO is defined as insertion of the UP Drug-Coated Device into the targeted FSO followed by 2 consecutive, complete inflations of the balloon.</description>
          <population>'Analysis per patient.</population>
          <units>frontal sinus ostia</units>
          <param>Count of Units</param>
          <units_analyzed>frontal sinus ostia</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>frontal sinus ostia</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Randomized Cohort: Estimated Frontal Sinus Ostia (FSO) Diameter</title>
        <description>The smallest and largest diameters of the FSO determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. FSO diameter estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort - Treatment Arm</title>
            <description>Randomized cohort (n=70 patients) which received the Drug-Coated Device to dilate randomized frontal sinus ostium.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort - Control Arm</title>
            <description>Randomized cohort (n=70) which received Control Device to dilate randomized contralateral frontal sinus ostium.&#xD;
Control Device: Sinus dilation device without drug</description>
          </group>
        </group_list>
        <measure>
          <title>Randomized Cohort: Estimated Frontal Sinus Ostia (FSO) Diameter</title>
          <description>The smallest and largest diameters of the FSO determined by an independent, blinded sinus surgeon based on the centralized video-endoscopy review. FSO diameter estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Largest Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.86"/>
                    <measurement group_id="O2" value="2.6" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smallest Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.44"/>
                    <measurement group_id="O2" value="2.1" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Cohort: Estimated Largest Frontal Sinus Ostia (FSO) Diameter</title>
        <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>Analysis per patient.</population>
        <group_list>
          <group group_id="O1">
            <title>PK Cohort-Safety</title>
            <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Cohort: Estimated Largest Frontal Sinus Ostia (FSO) Diameter</title>
          <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
          <population>Analysis per patient.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>frontal sinus ostia</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>frontal sinus ostia</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline pre-dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline post-dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Cohort: Estimated Smallest Frontal Sinus Ostia (FSO) Diameter</title>
        <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>Analysis per patient.</population>
        <group_list>
          <group group_id="O1">
            <title>PK Cohort-Safety</title>
            <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Cohort: Estimated Smallest Frontal Sinus Ostia (FSO) Diameter</title>
          <description>The smallest and largest diameters of the FSO are estimated endoscopically by probing with a 3-mm olive-shaped frontal sinus suction tip and reported in mm.</description>
          <population>Analysis per patient.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>frontal sinus ostia</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>frontal sinus ostia</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline pre-dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline post-dilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Cohort: Total Sino-Nasal Outcomes Test Score (SNOT-22)</title>
        <description>SNOT-22 is a validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by patient on a 6-point scale as follows: 0: No problem; 1: Very mild problem; 2: Mild or slight problem; 3: Moderate problem; 4: Severe problem; 5: Problem as bad as it can be.&#xD;
Sum of all 22 questions constitutes the total SNOT-22 score with a maximum total score equal to 110.</description>
        <time_frame>Baseline, Day 14 and Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Cohort-Safety</title>
            <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device</description>
          </group>
        </group_list>
        <measure>
          <title>PK Cohort: Total Sino-Nasal Outcomes Test Score (SNOT-22)</title>
          <description>SNOT-22 is a validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by patient on a 6-point scale as follows: 0: No problem; 1: Very mild problem; 2: Mild or slight problem; 3: Moderate problem; 4: Severe problem; 5: Problem as bad as it can be.&#xD;
Sum of all 22 questions constitutes the total SNOT-22 score with a maximum total score equal to 110.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>In the Randomized cohort each patient received the Drug-Coated Device (Treatment Arm) and Control Device (Control Arm) and thus the adverse events were collected per patient and not per intervention.&#xD;
In the PK cohort each patient received the Drug-Coated Device only and the adverse events were collected per patient.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants From Randomized Cohort</title>
          <description>Randomized cohort (n=70) used a randomized intra-patient design in which the Drug-Coated Device was used to dilate randomized frontal sinus ostium and Control Device was used to dilate contralateral frontal sinus ostium.&#xD;
Each patient received the Drug-Coated Device (Treatment Arm) and Control Device (Control Arm) and thus the adverse events are reported per patient in the Randomized Cohort. The adverse events were not collected per intervention.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device. Control Device: Sinus dilation device without drug.</description>
        </group>
        <group group_id="E2">
          <title>PK Cohort-Safety</title>
          <description>PK cohort (n=5) used a non-randomized design in which one Drug-Coated Device was used to dilate both frontal sinus ostia.&#xD;
Drug-Coated Device: 3000 mcg mometasone furoate-coated sinus dilation device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Campbell PhD, MPH Clinical Affairs Director</name_or_title>
      <organization>Intersect ENT</organization>
      <phone>6506412100</phone>
      <email>acampbell@intersectent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

